SG Americas Securities’s Mineralys Therapeutics MLYS Stock Holding History

SG Americas Securities’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Sell	60,963 -164,870	-73%	-$4.52M	﹤0.01%	1604
2026 Q1	$6.12M	Sell	225,833 -4,962	-2%	-$146K	0.01%	972
2025 Q4	$8.38M	Buy	230,795 +130,758	+131%	+$5.24M	0.01%	851
2025 Q3	$3.79M	Sell	100,037 -23,950	-19%	-$518K	0.01%	619
2025 Q2	$1.68M	Buy	123,987 +113,530	+1,086%	+$1.65M	0.01%	860
2025 Q1	$166K	Sell	10,457 -9,504	-48%	-$109K	﹤0.01%	2670
2024 Q4	$246K	Buy	19,961 +10,845	+119%	+$142K	﹤0.01%	1958
2024 Q3	$110K	Buy	+9,116	New	+$110K	﹤0.01%	2984
2024 Q1	–	Sell	-10,093	Closed	-$87K	–	3253
2023 Q4	$87K	Buy	+10,093	New	+$79.3K	﹤0.01%	2808

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SG Americas Securities's MLYS Position: Q2 2026 in Review

SG Americas Securities reduced its Mineralys Therapeutics (MLYS) stake by 73% in Q2 2026, selling an estimated $4.52M and leaving 60,963 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

SG Americas Securities first reported a position in MLYS in Q4 2023 and has held it in 9 quarters since. The position peaked at $8.38M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

SG Americas Securities held 60,963 shares of Mineralys Therapeutics worth $1.65M as of Q2 2026.
SG Americas Securities sold 164,870 Mineralys Therapeutics shares in Q2 2026, an estimated $4.52M.
Mineralys Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1604 holding.
SG Americas Securities first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 9 quarters since.
SG Americas Securities's Mineralys Therapeutics position peaked at $8.38M in Q4 2025.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.